Visterra, Inc. Announces Presentation Of Data At International Influenza Meeting On The Efficacy Of VIS410 For Treatment Of A Deadly Strain Of Avian Influenza

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Visterra, Inc., a clinical-stage biotechnology company that uses its proprietary technology platform to identify unique disease targets and design novel therapeutics for infectious diseases, today announced that new preclinical data for VIS410 will be presented at the 4th International Society for Influenza and Other Respiratory Virus Diseases Antiviral Group (isirv-Antiviral Group) Conference at the University of Texas in Austin, Texas, on June 2 - 4, 2015.

Help employers find you! Check out all the jobs and post your resume.